Harkin, Hatch Take Swing At FDA Pitch To Evaluate NDIs As Food Additives

The staunch industry allies explain their concerns about the potential for regulating new dietary ingredients as food additives in a letter to FDA Commissioner Hamburg. They point out DSHEA includes “an essential exclusion of dietary ingredients from the statutory definition of food additives.”

Sens. Tom Harkin and Orrin Hatch likely have pulled the plug on the potential for FDA applying its food additive standards to evaluating new dietary ingredients.

Harkin, D-Iowa, and Hatch, R-Utah, the primary Senate authors of the Dietary Supplement Health and Education Act of 1994 and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

Business Background Of New CDER Director George Tidmarsh

 

George Tidmarsh has extensive experience in the biopharmaceutical industry and lead several drugs to FDA approval.

‘Prescription Drugs Are Not Golf Balls’: FTC/DoJ Solicit Clashing Opinions On Patents

 

Innovator drug advocates argued that the number of patents asserted by industry is not too dissimilar to other fields. But should drugs be compared to golf balls?

US FDA Could Seek Stronger Warnings On SSRI Antidepressant Risks During Pregnancy

 
• By 

Testimony during a July 21 ‘expert panel’ could help justify stronger warnings across the class about potential adverse effects on mother and baby. Panelists ranged from clinicians who said depression during pregnancy should be treated, to those who said sadness has been “medicalized."

Will Tidmarsh’s Industry Experience Translate As US FDA’s Chief Drug Regulator?

 

The long-time industry executive led several drug approvals but may have a lot to learn about the intimate details of application review and the Center for Drug Evaluation and Research.

More from North America